EXPERIENCE OF USING THE TEST SYSTEM «GASTROPANEL» IN THE PREVENTIVE MEDICAL EXAMINATION OF WORKFORCE IN JSC RZD

Non-invasive diagnosis of the gastric mucosa was carried out in 181 people in the preventive medical examination of workforce in JSC RZD. A set of diagnostics from Vector-Best (Novosibirsk, Russia) was used for enzyme immunoassay of pepsinogen I, pepsinogen II, and immunoglobulins for Helicobacter pylori. The prevalence of H. pylori infection in more than half of the employees, the presence of deviations of biomarkers from the norm in more than one in three employees were revealed. Laboratory signs of atrophy were detected eight times less frequently than signs of inflammation of the gastric mucosa, but when infected with H. pylori and increased with age.

Helicobacter pylori infection: place of serological and cultural diagnostics in clinical guidelines

The purpose of this work was to familiarize doctors with the methods and significance of serological and cultural diagnostics of H. pylori infection on the example of the test for diagnosing the state of the gastric mucosa «Gastropanel». Blood serum tests were performed for 1057 patients and 122 healthy people aged 18-64 years: pepsinogen I (PG I), pepsinogen II (PG II), gastrin-17 (G-17), basal/stimulated), antibodies (IgGHp) to H. pylori (Biohit Oyj, Finland). The medians of the studied group indicators did not exceed the reference intervals. 398 (34%) patients have negative H. pylori status (IgGHp-). 275 (26%) patients with serum PG I≤70 mcg/ml were identified. The ratio of PG I/II≤3 in 84 (8%), 36 of them (43% of the group PG I/II≤3) - IgGHp-.

Association of Helicobacter pylori Infection with Respiratory Diseases in Cameroon Patients, Using GastroPanel® Serological Biomarkers (Pepsinogen I; Pepsinogen II; Gastrin-17; Helicobacter pylori IgG)

Introduction: Helicobacter pylori (H. pylori) is a microaerophilic gram-negative bacterium that colonizes the gastric mucosa and provokes inflammation and immune responses throughout life with liberation of diversecytotoxique substances dependent on host. Infection to H. pylori has been associated to a number of respiratory complications, including chronic obstructive pulmonary dieases, bronchectasis, asthma, tuberculosis and lung cancer. Epidemiological data on the association of H. pylori infection respiratory diseases are rare in Cameroon. We sought to evaluate the prevalence H. pylori infection among patient with respiratory diseases. Methodology: Blood samples were aseptically collected for the measurements Helicobacter pylori IgG antibodies, pepsinogene I et II levels, gastrine-17. The blood samples required for the study were collected prospectively. Ethical clairance was obtained from the Centre Regional Ethics Committee for Human Sciences. An authorization of research was obtained from the authorities of Jamot Hospital of Yaounde. All participants signed an informed consent form. Results: The GastroPanel® results showed that the prevalence of H. pylori infection was 42(46.67%). We observed an H. pylori seroprevalence of 75%, 41.9%, 50.0% and 33,33% amongst sujects with bronchitis, Tuberculosis, Asthma and pneumonia respectively.

Non-invasive laboratory markers assessing efficacy of Helicobacter pylori eradication therapy

Effective eradication of Helicobacter pylori infection is an important means to reduce the risk of precancerous changes in the gastric mucosa and prevention of gastric cancer. A search for non-invasive diagnostic tools for Helicobacter pylori infection, evaluation of the effectiveness of eradication remains of high importance.The aim of the study was to assess an informative value of detecting pepsinogen I and II as well as serum antibodies to Helicobacter pylori while assessing an efficacy of treated chronic Helicobacter gastritis and identifying preneoplastic changes in the stomach mucosa. There enrolled 113 male patients with chronic gastritis aged 41 to 76, average age- (56.7±0.7) years. Examination of patients was carried out at admission to the clinic, as well as at 2 and 12 months after administering a standard eradication therapy. It was found that Helicobacter pylori infection was detected in 101 (89.4%) patients. Groups of patients with effective eradication therapy were noted. A time-dependent level of antibodies to Helicobacter pylori, as well as measured concentration of pepsinogen I and II after the onset of eradication treatment were determined. Which were analyzed in connection with the results of histology examination of gastric mucosa biopsy specimens and expression of oncoproteins Ki-67, Bcl-2, c-erbB-2, p16 in the gastric mucosa depending on efficacy of eradication therapy. It is shown that effective eradication therapy was characterized by significantly decreased serum level of IgG antibodies to Helicobacter pylori 2 months after the onset of treatment. Moreover, a significantly decreased pepsinogen II and serum IgG antibodies to Helicobacter pylori during eradication therapy were accompanied by a significant decrease in Ki-67 expression in the gastric epithelium. Decreased concentration of pepsinogen II within the first year after Helicobacter pylori eradication therapy was due to a greater decrease in activity of inflammatory changes in the gastric mucosa than to dynamic changes in gastric atrophy and metaplasia. An inverse relation between the serum level of pepsinogen I and atrophy as well as intestinal metaplasia within the gastric mucosa were found.